Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic Surgery
Information source: Yonsei University
Information obtained from ClinicalTrials.gov on October 04, 2010
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Laparoscopic Nephrectomy; Postoperative IV-PCA
Intervention: Ondansetron (Drug); Ramosetron (Drug); Palonosetron (Drug)
Phase: N/A
Status: Not yet recruiting
Sponsored by: Yonsei University
Summary
The aim of this prospective randomized controlled study was to compare the prophylactic
effects of intravenous single dose of ondansetron, ramosetron, and palonosetron on
PCA-related nausea and vomiting after urologic laparoscopic surgery.
Clinical Details
Official title: Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic Surgery
Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention
Primary outcome: severity of nauseathe number of vomiting
Eligibility
Minimum age: 20 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- ASA I or II
- Patients aged (20-65 yr) Undergoing Laparoscopic Nephrectomy
- Patients who want a patient-controlled IV analgesia (IV-PCA)
Exclusion Criteria:
- History of allergy or hypersensitivity to 5-HT3 antagonist
- History of severe postoperative nausea/vomiting
- Prolonged QT interval on preoperative EKG
- Hypokalemia, Hypomagnesemia
- Intestinal obstruction
- Pregnant female or breast feeding mother
Locations and Contacts
Severance Hospital, Yonsei University College of Medicine, Seoul 120-752, Korea, Republic of
Additional Information
Starting date: August 2010
Last updated: July 23, 2010
|
